Possible serotonin syndrome arising from an interaction between nortiptyline and selegiline in a lady with parkinsonism

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Neurology

• Publication date

  2000-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s004150070101PMID 11127542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease

  1997cited by this paper
• Retrospective Study of Selegiline–Antidepressant Drug Interactions and a Review of the Literature

  1997cited by this paper
• The serotonin syndrome.

  1991cited by this paper

• Frequency and predictors of potential drug: Drug interactions in hospitalized patients with Parkinson's diseases

  2021cites this paper
• A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice

  2020cites this paper
• The serotonin syndrome is a life-threatening condition caused by increased serotonergic activity. (Boyer and Shannon, 2005) Three main symptom of serotonin syndrome are altered mental status, autonomic hyperactivity, and neuromuscular abnormalities (Table 1). Sign of serotonin syndrome vary in range

  2018cites this paper
• Síndrome serotoninérgico secundario a la combinación de venlafaxina y clomipramina. A propósito de un caso

  2016cites this paper
• Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló’s concentric sclerosis

  2016cites this paper
• Serotonin syndrome induced by a combination of venlafaxine and clomipramine. A case report.

  2016cites this paper
• Monoamine Reuptake Inhibitors in Parkinson's Disease

  2015cites this paper
• Baló's concentric sclerosis and tumefactive demyelination: a shared immunopathogenesis?

  2015cites this paper
• Extreme Blood Pressure After Ephedrine: Should We Rule Out Pheochromocytoma?

  2015cites this paper
• Disorders of body temperature.

  2014cites this paper
• Case Reports of Neuroleptic Malignant Syndrome in Context of Quetiapine Use

  2013cites this paper
• Pharmacologic Safety Concerns in Parkinson's Disease: Facts and Insights

  2011cites this paper
• An interesting case of serotonin syndrome precipitated by escitalopram

  2010cites this paper
• Emergency presentations of Parkinson's disease: early recognition and treatment are crucial for optimum outcome

  2010cites this paper
• Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline

  2007cites this paper
• Drug-drug interactions with levodopa modulating treatment responses in Parkinson's disease

  2007cites this paper
• Selegiline orally disintegrating tablet in the treatment of Parkinsons disease

  2006cites this paper
• Chapter 28 – Patients with Neurologic Conditions II. Movement Disorders, Multiple Sclerosis, and Other Neurologic Conditions

  2004cites this paper
• Pressor Response to Intravenous Tyramine in Healthy Subjects After Safinamide, a Novel Neuroprotectant With Selective, Reversible Monoamine Oxidase B Inhibition

  2003cites this paper
• Safety of Selegiline with Cold Medications

  2003cites this paper
• Depression in Parkinson’s disease

  2002cites this paper
• Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease

  2002cites this paper
• Depression in Parkinson's disease.

  2002cites this paper